Table 3.
Clinical and Pathological Characteristics Associated with High Tumor PD-L1 Positivity in Mismatch Repair Intact Grade 2 Endometrial Endometrioid Adenocarcinoma
| Variable | Tumor PD-L1 negative (69/132; 52%) |
Tumor PD-L1 high positive (21/132; 16%) |
p-value |
|---|---|---|---|
| Age in years | |||
| Mean (SD) | 59 (12) | 56 (12) | 0.260 |
| Median (Minimum-Maximum) | 60 (27-82) | 59 (30 – 77) | |
| Tumor size (mm) | |||
| Mean (SD) | 43 (26) | 35 (17) | 0.355 |
| Median (Minimum- Maximum) | 35 (13-127) | 31(12-75) | |
| Tumor stage, n (%) | |||
| I or II | 66 (96) | 18 (86) | 0.735 |
| III or IV | 3 (4) | 3 (14) | |
| Any myometrial invasion, n (%) | |||
| Yes | 44 (64) | 18 (86) | 0.065 |
| No | 25 (36) | 3 (14) | |
| Myometrial invasion present and ≥50%, n (%) | |||
| Yes | 7 (16) | 8 (44) | 0.017 |
| No | 37 (84) | 10 (56) | |
| Not applicable (no myometrial invasion) | 25 | 3 | |
| LVSI, n (%) | |||
| Yes | 8 (12) | 8 (38) | 0.005 |
| No | 61 (88) | 13 (62) | |
| Metastasis to pelvic lymph nodes, n (%) | |||
| Yes | 2 (5) | 3 (18) | 0.165 |
| No | 36 (95) | 14 (82) | |
| Metastasis to para-aortic lymph nodes, n (%) | |||
| Yes | 0 | 2 (18) | 0.146 |
| No | 17 (100) | 9 (82) | |
| PTEN IHC, n (%) | |||
| Positive | 42 (61) | 8 (38) | 0.148 |
| Heterogeneous | 2 (3) | 1 (5) | |
| Negative | 25 (36) | 12 (57) | |
| CD3 (mean cells/mm2, SD) | |||
| Overall | 800 (470) | 1174 (724) | 0.014 |
| Hotspot | 1287 (688) | 1963 (895) | 0.001 |
| Periphery | 729 (436) | 1214 (749) | 0.002 |
| Center | 811 (516) | 1134 (766) | 0.066 |
| CD8 (mean cells/mm2, SD) | |||
| Overall | 398 (293) | 804 (755) | .017 |
| Hotspot | 652 (441) | 1233 (859) | 0.001 |
| Periphery | 383 (275) | 882 (782) | 0.003 |
| Center | 379 (319) | 720 (782) | 0.073 |
| CD68 (mean cells/mm2, SD) | |||
| Overall | 176 (158) | 170 (106) | 0.650 |
| Hotspot | 286 (241) | 287 (159) | 0.499 |
| Periphery | 157 (152) | 171 (109) | 0.231 |
| Center | 193 (183) | 170 (118) | 0.963 |